Published Date: 09 Mar 2023
Recent studies have shown poor outcomes in infants and children with postnatal development.
Read Full NewsDESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.
A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?
High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.
Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.
1.
Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation
2.
Cancer during young adulthood carries long-term mental toll, study finds
3.
Glioma Outcomes Shaped by Subtype More Than Tx Sequence
4.
Massachusetts nurses with brain tumors: Department of Public Health 'in communication' with Newton-Wellesley
5.
Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar
1.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
2.
Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options
3.
The Science Behind Thrombolytic Drugs and Their Benefits
4.
Clinical Pharmacology of Hypoxia-Activated Anticancer Prodrugs
5.
Does Lactate Signal Anemia? Exploring the Complexities of Hyperlactatemia and Red Blood Cell Health
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
Blood Clotting Disorders Explained
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation